Pediatrix Medical Group Inc (MD) concluded trading on Thursday at a closing price of $12.82, with 0.48 million shares of worth about $6.2 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.31% during that period and on April 17, 2025 the price saw a loss of about -2.44%. Currently the company’s common shares owned by public are about 85.87M shares, out of which, 84.65M shares are available for trading.
Stock saw a price change of -5.46% in past 5 days and over the past one month there was a price change of -9.91%. Year-to-date (YTD), MD shares are showing a performance of -2.29% which increased to 43.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.62 but also hit the highest price of $17.67 during that period. The average intraday trading volume for Pediatrix Medical Group Inc shares is 671.80K. The stock is currently trading -8.06% below its 20-day simple moving average (SMA20), while that difference is down -10.21% for SMA50 and it goes to 2.18% higher than SMA200.
Pediatrix Medical Group Inc (NYSE: MD) currently have 85.87M outstanding shares and institutions hold larger chunk of about 98.29% of that.
The stock has a current market capitalization of $1.10B and its 3Y-monthly beta is at 1.26. It has posted earnings per share of -$1.20 in the same period. It has Quick Ratio of 1.47 while making debt-to-equity ratio of 0.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MD, volatility over the week remained 2.94% while standing at 4.30% over the month.
Stock’s fiscal year EPS is expected to rise by 2.09% while it is estimated to increase by 5.39% in next year. EPS is likely to shrink at an annualized rate of 2.86% for next 5-years, compared to annual growth of 41.89% made by the stock over the past 5-years.
Coverage by Jefferies stated Pediatrix Medical Group Inc (MD) stock as a Buy in their note to investors on September 26, 2024, suggesting a price target of $14 for the stock. On June 07, 2024, Deutsche Bank Upgrade their recommendations, while on September 27, 2021, SVB Leerink Initiated their ratings for the stock with a price target of $29. Stock get a Hold rating from Stifel on June 23, 2021.
